Rhythm Pharmaceuticals, Inc. (RYTM)
Stock Price:
$21.01 USD
-0.89 (-4.06%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
926.37M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-145.92M |
| Shares Out |
44.09M |
| EPS (ttm) |
-3.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$21.01 |
| Previous Close |
$21.90 |
| Change ($) |
-0.89 |
| Change (%) |
-4.06% |
| Day's Open |
21.96 |
| Day's Range |
21.00 - 22.06 |
| Day's Volume |
78,845 |
| 52-Week Range |
12.99 - 25.86 |
More Stats
| Market Cap |
926.37M |
| Enterprise Value |
671.99M |
| Earnings Date (est) |
Aug 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.09M |
| Float |
25.33M |
| EPS (basic) |
-3.79 |
| EPS (diluted) |
-3.76 |
| FCF / Share |
-2.95 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.68M |
| Short Ratio |
10.34 |
| Short % of Float |
5.48% |
| Beta |
0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.82 |
| Revenue |
n/a |
| Operating Income |
-150.78M |
| Net Income |
-145.92M |
| Free Cash Flow |
-130.04M |
| Net Cash |
254.38M |
| Net Cash / Share |
5.77 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-36.08% |
| ROE |
-61.62% |
| ROIC |
-91.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$32.88*
(56.50% upside)
Low
18.0
Current: 21.01
High
43.0
Target: 32.88
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -146 | -78.42 | -32.41 | -25.91 | -10.57 |
| Net Income | -141 | -74.06 | -37.58 | -25.87 | -11.07 |
| Shares Outstanding | 36.42 | 31.00 | 13.27 | 10.20 | 10.20 |
| Earnings Per Share | -3.86 | -2.39 | -2.83 | -2.85 | -1.18 |
| Operating Cash Flow | -123 | -62.06 | -29.46 | -23.22 | -6.75 |
| Capital Expenditures | -3.39 | -0.72 | -0.13 | -1.06 | -0.02 |
| Free Cash Flow | -126 | -62.78 | -29.59 | -24.28 | -6.77 |
| Cash & Equivalents | 293 | 252 | 148 | 10.76 | 35.09 |
| Total Debt | 3.56 | - | - | - | - |
| Net Cash / Debt | 289 | 252 | 148 | 10.76 | 35.09 |
| Assets | 309 | 260 | 152 | 12.34 | 37.28 |
| Liabilities | 27.50 | 13.95 | 6.95 | 5.04 | 5.27 |
| Book Value | 281 | 246 | 145 | -32.70 | -8.00 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Rhythm Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
70 |
| CEO |
Hunter C. Smith |
Stock Information
| Ticker Symbol |
RYTM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RYTM |
| IPO Date |
October 5, 2017 |
Description
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.